Charles A. Rowland, Jr. has been the CEO of Viking Therapeutics since July 2017 and brings a wealth of experience in the biopharmaceutical industry. He previously served as the president and CEO of Aurinia Pharmaceuticals and held leadership roles in...

Charles A. Rowland, Jr. has been the CEO of Viking Therapeutics since July 2017 and brings a wealth of experience in the biopharmaceutical industry. He previously served as the president and CEO of Aurinia Pharmaceuticals and held leadership roles in major companies like ViroPharma and Endo Pharmaceuticals. Rowland has been on the board of several companies, demonstrating his influence in the biotech field. His education includes a degree in Accounting from Saint Joseph's University and an MBA from Rutgers University. In his time at Viking, he has overseen significant growth and initiatives in drug development. Rowland's strategic insights into corporate finance and operations are key to guiding Viking's direction, especially as the company focuses on innovative treatments. He’s not just into biotech; he has also been involved in various boards and committees, indicating his broader impact on the industry. In 2023, Rowland received substantial compensation reflecting his leadership in navigating the company through complex challenges.